As COX-2 maintains the CSC phenotype by activating DRP1, selective COX-2 inhibitors, such as resveratrol, celecoxib, and etodolac, are reported to reduce the expression levels of stemness genes, the ratio of SP+ subpopulations, and the tumorsphere formation capacity in NPC, bladder cancer, and glioblastoma [120, 122, 123] (Fig. 3B). This evidence concerns the gene DNM1L and glioblastoma.